Type II Glycoengineered Anti-CD20 Antibody MIL62 or Cyclosporine in Chinese Primary Membranous Nephropathy: A Multicenter, Randomized, Open-Label Phase 1b/2 Trial
用户aKgJC6g3RnhA
1个月前
92
10
已完结
1. 系统已在2025-08-18 10:12:17对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
文献链接: https://journals.lww.com/10.1681/ASN.2024yaqz098x
其他信息:
出版社: Ovid Technologies (Wolters Kluwer Health)
作者: Zhao Cui; Zhang Yimiao; Heng Li; Hua Zhou; Hong Li Lin; Guangqun Xing; Wei Chen; Wei Liang; Ping Luo; Chen Xiao Lan; Hui Xu; Yan Zha; Yue Wang; Xing Chen; Zhaohui Ni; Junjun Zhang; Wanhong Lu; Li Hua Zhang; Ming-Hui Zhao; Min Wei; Song Meng; Liang Jinjin; Feng Li
